{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010508","form_type":"8-K","ticker":"SENS","cik":"0001616543","company_name":"Senseonics Holdings, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.490406+00:00","generated_at":"2026-05-17T19:30:33.201511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Senseonics Q2 revenue $6.6M (+37% YoY); net loss narrows to $14.5M","bullets":["Revenue $6.6M, up 37% YoY, driven by 79% U.S. new patient starts growth to $4.9M.","Net loss $14.5M ($0.02 loss per share) vs $20.3M loss in Q2 2024; gross profit $3.1M vs $0.3M.","FY2025 revenue guidance reaffirmed at $34-38M; gross margins expected 32.5%-37.5%.","Raised $77.8M gross proceeds ($57.5M public offering + $20.3M Abbott private placement).","Entered development agreement with Sequel Med Tech to integrate Eversense 365 with twiist AID system."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010508","json":"https://secwatch.observer/filing/0001558370-25-010508.json","markdown":"https://secwatch.observer/filing/0001558370-25-010508.md","text":"https://secwatch.observer/filing/0001558370-25-010508.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616543/000155837025010508/0001558370-25-010508-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616543/000155837025010508/sens-20250806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:30:33.201511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}